However, these methods either require (artificial) exogenous protein expression in HER2 non-expressing cell lines, are incapable of sufficiently resolving single protein distribution, require secondary signal amplification leading to steric hindrance and thus insufficient labeling, or provide false positive signals at the higher receptor densities found in cancer cells [34,35]. This evidence concerns the gene ERBB2 and cancer.